Log in

Relevant bibliographies by topics / Oxaliplatin / Journal articles

To see the other types of publications on this topic, follow the link: Oxaliplatin.

Journal articles on the topic 'Oxaliplatin'

Author: Grafiati

Published: 4 June 2021

Last updated: 9 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Oxaliplatin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ye, Tong, Chen Wu, Jintong Na, Xiyu Liu, and Yong Huang. "Multi-Pathway Study for Oxaliplatin Resistance Reduction." Current Issues in Molecular Biology 47, no. 3 (March 4, 2025): 172. https://doi.org/10.3390/cimb47030172.

Full text

Abstract:

Chemotherapy for cancer frequently uses platinum-based medications, including oxaliplatin, carboplatin, and cisplatin; however, due to their high systemic toxicity, lack of selectivity, drug resistance, and other side effects, platinum-based medications have very limited clinical application. As a first-line medication in antitumor therapy, oxaliplatin must be administered to minimize side effects while achieving anticancer objectives. A new CDC7 inhibitor called XL413 has demonstrated promising antitumor therapeutic effects in a variety of malignant tumors and may have anticancer properties.

APA, Harvard, Vancouver, ISO, and other styles

2

Ain, Noor ul, Nusrat Bano, Anwar Ejaz Beg, Kamran Hameed, Talha Bin Fayyaz, and Rafia Sadaf. "HEMATOLOGICAL TOXICITY IN RATS;." Professional Medical Journal 24, no. 02 (February 14, 2017): 342–46. http://dx.doi.org/10.29309/tpmj/2017.24.02.525.

Full text

Abstract:

Objectives: Oxaliplatin causes hematological toxicities in clinical setting whichlimits its efficacy. The aim of this study is to investigate the therapeutic effects of Andrographispaniculata against hematological toxicity caused by oxaliplatin. Study design: Experimentalanimal study. Period: Study takes 8 month from March 2015 to Oct 2015. Setting: Dow universityanimal house. Method: Wistar albino male rats, divided into 3 equals groups (n=6): GroupN* was a control group (0.9% normal saline), Group NP0 was Oxaliplatin treated group andGroup NP1 was prophylactically treated with Andrographis p

APA, Harvard, Vancouver, ISO, and other styles

3

Grothey, A., D. A. Nikcevich, J. A. Sloan, J. W. Kugler, P. T. Silberstein, T. Dentchev, D. B. Wender, H. E. Windschilt, X. Zhao, and C. L. Loprinzi. "Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 4025. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4025.

Full text

Abstract:

4025 Background: Cumulative sNT is the dose-limiting toxicity of oxaliplatin which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant setting. We recently demonstrated the protective effect of CaMg against oxaliplatin-induced sNT as assessed by NCI-CTC (Nikcevich ASCO 2008). It is unclear, though, if CaMg reduced acute and/or chronic, cumulative sNT. Methods: 104 pts with colon cancer undergoing adjuvant therapy with FOLFOX were randomized to IV CaMg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo (PL) in a

APA, Harvard, Vancouver, ISO, and other styles

4

Pires, Lívia Márcia Vidal, and Patrícia Dos Santos Claro Fuly. "Mapeamento de fatores clínicos preditivos da neuropatia sensorial periférica induzida por oxaliplatina: revisão sistemática." Revista Recien - Revista Científica de Enfermagem 11, no. 35 (September 23, 2021): 382–97. http://dx.doi.org/10.24276/rrecien2021.11.35.382-397.

Full text

Abstract:

O objetivo deste estudo foi realizar um mapeamento dos fatores clínicos preditivos da Neuropatia Sensorial Periférica induzida pela Oxaliplatina. Para tanto, foi realizada uma revisão sistemática, elaborada a partir das recomendações da diretriz PRISMA. A estratégia PICO também foi utilizada para formular a questão de pesquisa e orientar a busca nas bases de dados: PubMed, Embase, Scopus, BVS/IBECS e CINAHL. Foram selecionadas 26 publicações para análise final e inclusão na revisão. As publicações foram classificadas quanto ao nível de evidência e grau de recomendação, de acordo com o sistema

APA, Harvard, Vancouver, ISO, and other styles

5

Cho, Soohee, Kristen Miller, Jacqueline Rowley, Ashley Sabus, Shelby Winzent-Oonk, Stacy Bray, Jane Koo, and Jean Mulcahy Levy. "OTHR-03. Oxaliplatin as a hearing-sparing alternative to carboplatin in tandem autologous stem cell transplants in pediatric CNS malignancy." Neuro-Oncology 24, Supplement_1 (June 1, 2022): i147. http://dx.doi.org/10.1093/neuonc/noac079.542.

Full text

Abstract:

Abstract BACKGROUND: Intensive chemotherapy with tandem autologous stem cell transplants (autoSCT) is shown to improve survival for children with CNS malignancy. Platinum-based chemotherapeutic agents in these regimens, mainly cisplatin and carboplatin, have resulted in significant sensorineural hearing loss. Oxaliplatin, a newer platinum-based agent, is considered less ototoxic. Empiric substitution of oxaliplatin for carboplatin in preparative regimens for autoSCT have been tried. However, the survival and ototoxicity outcomes have not been studied. OBJECTIVE: To compare the overall survival

APA, Harvard, Vancouver, ISO, and other styles

6

Connors, Jeremy S., Linda Zhang, Koji Sasaki, Courtney D. DiNardo, Nicholas J. Short, Naval Daver, Gautam Borthakur, et al. "Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms." Blood 142, Supplement 1 (November 28, 2023): 4220. http://dx.doi.org/10.1182/blood-2023-190672.

Full text

Abstract:

Introduction As a DNA-damaging agent, platinum-based chemotherapy serves as a cornerstone in cancer treatment. However, its widespread use has been associated with increased incidence of therapy-related myeloid neoplasms (t-MNs). Among the three most commonly used platinum chemotherapies - cisplatin, carboplatin, and oxaliplain - oxaliplatin presents a distinctive clinical usage and toxicity profile. Predominantly utilized in treating gastrointestinal tract (GI) cancers, oxaliplatin manifests a distinct toxicity pattern when compared to its counterparts. This variance is supported by a previou

APA, Harvard, Vancouver, ISO, and other styles

7

Lipp and Hartmann. "Platinverbindungen: Metabolismus, Toxizität und supportive Strategien." Praxis 94, no. 6 (February 1, 2005): 187–98. http://dx.doi.org/10.1024/0369-8394.94.6.187.

Full text

Abstract:

Mit Oxaliplatin wurde der erste Vertreter der DACH-Platin-Verbindungen in die Klinik eingeführt (DACH: Diaminocyclohexan), der bei guter Verträglichkeit die höchste Aktivität zur Behandlung des fortgeschrittenen kolorektalen Karzinoms aufweist. Aufgrund der hohen, gegenüber Cisplatin besseren in vitro-Aktivität des Oxaliplatins auch gegenüber anderen Tumorentitäten sind die klinischen Studien mit Oxaliplatin in den letzten Jahren erheblich ausgeweitet worden. Der breite Einsatz der genannten Platinverbindungen darf allerdings nicht darüber hinwegtäuschen, dass diese Wirkstoffe über beachtliche

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1378 (November 2011): 27. http://dx.doi.org/10.2165/00128415-201113780-00098.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1384 (January 2012): 43. http://dx.doi.org/10.2165/00128415-201213840-00174.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1385 (January 2012): 35. http://dx.doi.org/10.2165/00128415-201213850-00129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1388 (February 2012): 24. http://dx.doi.org/10.2165/00128415-201213880-00093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1389 (February 2012): 34. http://dx.doi.org/10.2165/00128415-201213890-00124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1390 (February 2012): 28–29. http://dx.doi.org/10.2165/00128415-201213900-00109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1390 (February 2012): 29. http://dx.doi.org/10.2165/00128415-201213900-00112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1391 (March 2012): 32. http://dx.doi.org/10.2165/00128415-201213910-00119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 714 (August 1998): 12. http://dx.doi.org/10.2165/00128415-199807140-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1161 (July 2007): 20. http://dx.doi.org/10.2165/00128415-200711610-00064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1166 (August 2007): 19. http://dx.doi.org/10.2165/00128415-200711660-00058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1174 (October 2007): 21–22. http://dx.doi.org/10.2165/00128415-200711740-00062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1180 (December 2007): 32. http://dx.doi.org/10.2165/00128415-200711800-00099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1187 (February 2008): 21. http://dx.doi.org/10.2165/00128415-200811870-00068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1188 (February 2008): 18–19. http://dx.doi.org/10.2165/00128415-200811880-00060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1189 (February 2008): 27–28. http://dx.doi.org/10.2165/00128415-200811890-00086.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1191 (March 2008): 20. http://dx.doi.org/10.2165/00128415-200811910-00063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1192 (March 2008): 27. http://dx.doi.org/10.2165/00128415-200811920-00072.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1194-1195 (March 2008): 28. http://dx.doi.org/10.2165/00128415-200811940-00102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1123 (October 2006): 15. http://dx.doi.org/10.2165/00128415-200611230-00045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1128 (November 2006): 15. http://dx.doi.org/10.2165/00128415-200611280-00048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1129 (November 2006): 16. http://dx.doi.org/10.2165/00128415-200611290-00055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1138 (February 2007): 21–22. http://dx.doi.org/10.2165/00128415-200711380-00063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1140 (February 2007): 17. http://dx.doi.org/10.2165/00128415-200711400-00058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1141 (March 2007): 17–18. http://dx.doi.org/10.2165/00128415-200711410-00061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1149 (April 2007): 19–20. http://dx.doi.org/10.2165/00128415-200711490-00058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1156 (June 2007): 20. http://dx.doi.org/10.2165/00128415-200711560-00062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1160 (July 2007): 24–25. http://dx.doi.org/10.2165/00128415-200711600-00068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1360 (July 2011): 29. http://dx.doi.org/10.2165/00128415-201113600-00099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1361 (July 2011): 31–32. http://dx.doi.org/10.2165/00128415-201113610-00111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1363 (August 2011): 31. http://dx.doi.org/10.2165/00128415-201113630-00122.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1366 (August 2011): 24. http://dx.doi.org/10.2165/00128415-201113660-00090.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (September 2011): 31–32. http://dx.doi.org/10.2165/00128415-201113680-00115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (September 2011): 32. http://dx.doi.org/10.2165/00128415-201113680-00117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (September 2011): 32. http://dx.doi.org/10.2165/00128415-201113680-00119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1370 (September 2011): 30. http://dx.doi.org/10.2165/00128415-201113700-00105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1371 (October 2011): 29. http://dx.doi.org/10.2165/00128415-201113710-00109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1374 (October 2011): 28. http://dx.doi.org/10.2165/00128415-201113740-00100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1375 (October 2011): 24. http://dx.doi.org/10.2165/00128415-201113750-00080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1375 (October 2011): 24. http://dx.doi.org/10.2165/00128415-201113750-00082.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

L??vi, Francis, Gerard Metzger, Claire Massari, and Gerard Milano. "Oxaliplatin." Clinical Pharmacokinetics 38, no. 1 (January 2000): 1–21. http://dx.doi.org/10.2165/00003088-200038010-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Carlson, Robert. "Oxaliplatin." Inpharma Weekly &NA;, no. 1130 (March 1998): 3–4. http://dx.doi.org/10.2165/00128413-199811300-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 772 (October 1999): 10. http://dx.doi.org/10.2165/00128415-199907720-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!